Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Pyoderma Clinical Trial

Official title:
Opened, Multicenter, Randomized, in Parallel Groups Comparative Study to Assess Efficacy and Safety of Dioxidin®, Solution for Topical and External Application 0.025% (Valenta Farm, Russia) and Miramistin®, Solution for Topical Application 0.01% (Infamed K LLC, Russia) in Treatment of Superficial Pyoderma

Status Completed

Clinical Trial Summary

The study is aimed to: - evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, - evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pyoderma

Clinical Trial Details

NCT number	NCT05561816
Study type	Interventional
Source	Valenta Pharm JSC
Contact
Status	Completed
Phase	Phase 3
Start date	July 19, 2022
Completion date	December 20, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00884728` - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory	N/A
Recruiting	`NCT04901325` - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Phase 2
Completed	`NCT04895566` - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma	Early Phase 1
Withdrawn	`NCT00202891` - Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)	Phase 4
Recruiting	`NCT02280733` - A Real World, Observational Registry of Chronic Wounds and Ulcers